SMARCC2 and glioma: Strengthening the credibility of this conclusion, analysis of the survival statistics of 136 patients who underwent postoperative radiotherapy and chemotherapy also indicated that low expression of SMARCC2 was associated with poor prognosis of glioma (Fig. 1C).